RARE DISEASERESEARCH ATLAS

ORPHA:29

Mevalonic aciduria

medium confidenceSubtype of disorder

Also known as: Complete mevalonate kinase deficiency · MVA

Publications

425

69.3th percentile

Trials

0

Interventional, condition-specific

Researchers

1,127

Distinct authors in sample

Gene link

MVK

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare, severe form of mevalonate kinase deficiency (MKD) characterized by features, , psychomotor delay, ocular involvement, , , , and recurrent inflammatory episodes.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

HIDS · MKD · complete mevalonate kinase deficiency · hyperimmunoglobulin D with periodic fever syndrome · mevalonic aciduria

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — MVK

  2. LiteraturePresent

    425 matched papers (217 in last 10 years) Source

  3. Phenotype characterisedPresent

    68 HPO annotations (e.g. Hypotonia; Ataxia; Generalized hypotonia) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (MVK).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

68

Associated phenotypes · MONDO:0012481

  • Hypotonia
  • Ataxia
  • Generalized hypotonia
  • Cataract
  • Microcephaly

Showing 5 of 68 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

425

425 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

425 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

217 in the last 10 years · medium confidence · 69.3th percentile (publications denominator)

Phrase hits: 418 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,127

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Marcuzzi A9 papers · 2022

    Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy. marcuzzi@burlo.trieste.it

    Papers in Europe PMC
  2. 02
    Piscianz E8 papers · 2019

    Institute for Maternal and Child Health-IRCCS "Burlo Garofolo", via dell'Istria, 65/1, Trieste 34137, Italy. elisa.piscianz@gmail.com.

    Papers in Europe PMC
  3. 03
    Waterham HR8 papers · 2024

    Clinical Chemistry and Pediatrics, Academic Medical Center, Amsterdam, The Netherlands.

    Papers in Europe PMC
  4. 04
    Crovella S7 papers · 2017

    Institute for Maternal and Child Health—IRCCS ‘Burlo Garofolo' , Trieste,

    Papers in Europe PMC
  5. 05
    Frenkel J6 papers · 2024

    Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands.

    Papers in Europe PMC
  6. 06
    Gattorno M6 papers · 2024

    Reumatology Unit and.

    Papers in Europe PMC
  7. 07
    Hoffmann GF6 papers · 2023

    Centre for Pediatric and Adolescent Medicine, Im Neuenheimer Feld 669, D-69120, Heidelberg, Germany.

    Papers in Europe PMC
  8. 08
    Haas D5 papers · 2022

    Department of General Pediatrics, University Children's Hospital Heidelberg, Im Neuenheimer Feld 150, D-69120 Heidelberg, Germany. dorothea.haas@med.uni-heidelberg.de

    Papers in Europe PMC
  9. 09
    Rigante D5 papers · 2022

    Institute of Pediatrics, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy. drigante@gmail.com.

    Papers in Europe PMC
  10. 10
    Simon A5 papers · 2022

    Department of Internal Medicine, Radboudumc Expertise Centre for Immunodeficiency and Autoinflammation, Radboud University Medical Centre, Nijmegen, Netherlands.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Mevalonic aciduria — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Mevalonic aciduria" OR "Complete mevalonate kinase deficiency" OR "hyperimmunoglobulin D with periodic fever syndrome") OR ("MVK syndrome" OR "MVK-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Mevalonic aciduria" OR "Complete mevalonate kinase deficiency" OR "hyperimmunoglobulin D with periodic fever syndrome"

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: MVA; HIDS; MKD

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 3 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T12:09:01.745Z